Raymond James Financial
SGMO

Raymond James Financial’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Raymond James Financial’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,544
Closed -$8.41K – 6456
2025
Q2 		$8.41K Sell
15,544
-1,000
-6% -$594 ﹤0.01% 5989
2025
Q1 		$10.8K Buy
+16,544
New +$17.5K ﹤0.01% 4773

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Raymond James Financial's SGMO Position: Q3 2025 in Review

Raymond James Financial sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 15,544 shares — an estimated $8.41K sold.

Raymond James Financial first reported a position in SGMO in Q1 2025 and held it in 2 quarters. The position peaked at $10.8K in Q1 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

  • Raymond James Financial reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 15,544 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $8.41K.
  • Raymond James Financial first reported a position in SANGAMO THERAPEUTICS INC in Q1 2025 and held it in 2 quarters.
  • Raymond James Financial's SANGAMO THERAPEUTICS INC position peaked at $10.8K in Q1 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.